Masashi Aoki Selected Research

bimagrumab

1/2021	Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
12/2019	[Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): Japanese cohort data].
1/2019	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masashi Aoki Research Topics

Disease

41	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/2022 - 04/2003
23	Neuromyelitis Optica (Devic's Disease) 01/2022 - 01/2012
14	Disease Progression 11/2021 - 12/2002
11	Optic Neuritis (Retrobulbar Neuritis) 01/2022 - 06/2013
11	Multiple Sclerosis 11/2021 - 10/2012
9	Parkinson Disease (Parkinson's Disease) 11/2021 - 01/2011
7	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 06/2013
7	Atrophy 01/2022 - 05/2004
7	Inclusion Body Myositis 01/2021 - 07/2014
7	Dysferlinopathy 01/2020 - 05/2005
7	Muscular Diseases (Myopathy) 01/2017 - 12/2005
7	Miyoshi myopathy 04/2013 - 12/2002
5	Muscular Atrophy (Muscle Atrophy) 01/2020 - 05/2004
5	Muscle Weakness 06/2015 - 06/2007
4	Motor Neuron Disease (Primary Lateral Sclerosis) 06/2022 - 09/2010
4	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 11/2021 - 01/2013
4	Encephalitis (Encephalitis, Rasmussen) 01/2020 - 02/2005
4	Myasthenia Gravis 12/2019 - 11/2016
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2018 - 01/2011
3	Sarcoma (Soft Tissue Sarcoma) 06/2022 - 01/2017
3	COVID-19 01/2022 - 01/2021
3	Corticobasal Degeneration 11/2021 - 11/2016
3	Parkinsonian Disorders (Parkinsonism) 11/2021 - 11/2016
3	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 11/2016
3	Nervous System Diseases (Neurological Disorders) 01/2021 - 01/2013
3	Leukocytosis (Pleocytosis) 02/2020 - 08/2014
3	Juvenile Amyotrophic Lateral Sclerosis 2 01/2016 - 10/2008
3	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2016 - 01/2012
3	X-Linked Bulbo-Spinal Atrophy 05/2014 - 01/2006
3	type 2B Limb-girdle muscular dystrophy 04/2013 - 11/2005
3	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 04/2013 - 11/2005
3	Distal Myopathies (Distal Muscular Dystrophy) 09/2012 - 10/2004
2	Infections 01/2022 - 01/2021
2	Vision Disorders (Hemeralopia) 01/2022 - 01/2012
2	Fatigue 01/2021 - 06/2015
2	Dystonia (Limb Dystonia) 01/2021 - 01/2013
2	Gliosis 01/2021 - 01/2018
2	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2021 - 12/2002
2	Aphasia (Dysphasia) 06/2020 - 01/2018
2	Myelitis 01/2020 - 01/2014
2	Neutral Lipid Storage Disease with Myopathy 01/2020 - 07/2014
2	Encephalomyelitis (Myeloencephalitis) 01/2020 - 01/2012
2	Muscular Dystrophies (Muscular Dystrophy) 01/2020 - 01/2020
2	Respiratory Insufficiency (Respiratory Failure) 04/2019 - 01/2008
2	Nausea 04/2019 - 06/2013
2	Hemorrhage 01/2019 - 01/2008
2	Neuroinflammatory Diseases 01/2018 - 11/2016
2	Thymoma (Thymic Carcinoma) 11/2016 - 01/2014
2	Thymus Hyperplasia 11/2016 - 01/2014
2	Autoimmune Diseases (Autoimmune Disease) 09/2016 - 06/2013
2	Poisoning 01/2016 - 05/2015
2	Hiccup (Hiccups) 01/2016 - 06/2013

Drug/Important Bio-Agent (IBA)

17	Superoxide Dismutase-1IBA 01/2021 - 04/2003
15	AntibodiesIBA 01/2022 - 02/2005
15	DysferlinIBA 01/2020 - 12/2002
13	Proteins (Proteins, Gene)FDA Link 01/2020 - 02/2005
10	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 02/2014
8	AutoantibodiesIBA 05/2021 - 06/2013
8	Immunoglobulin G (IgG)IBA 01/2021 - 01/2009
8	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2019 - 11/2007
6	Aquaporin 4IBA 10/2021 - 06/2013
6	SteroidsIBA 01/2021 - 01/2012
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2013
5	SynucleinsIBA 01/2019 - 01/2011
4	Complement System Proteins (Complement)IBA 01/2021 - 01/2013
4	CytokinesIBA 02/2020 - 08/2014
4	Pharmaceutical PreparationsIBA 01/2020 - 01/2004
4	Creatine Kinase (Creatine Phosphokinase)IBA 04/2013 - 05/2004
3	Retinaldehyde (Retinal)IBA 01/2022 - 04/2016
3	Prednisolone (Predate)FDA LinkGeneric 04/2021 - 01/2018
3	bimagrumabIBA 01/2021 - 01/2019
3	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2020 - 05/2006
3	EnzymesIBA 04/2019 - 12/2014
3	Neuroprotective AgentsIBA 01/2019 - 07/2005
3	Corticotropin-Releasing HormoneIBA 01/2016 - 01/2012
2	DNA-Binding Proteins (DNA Binding Protein)IBA 06/2022 - 08/2019
2	THK5351IBA 01/2021 - 11/2016
2	Levodopa (L Dopa)FDA LinkGeneric 01/2021 - 07/2018
2	Intravenous Immunoglobulins (IVIG)FDA Link 01/2021 - 01/2009
2	Phosphotransferases (Kinase)IBA 09/2020 - 02/2019
2	Triglycerides (Triacylglycerol)IBA 01/2020 - 07/2014
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2018
2	Riluzole FDA LinkGeneric 04/2019 - 06/2015
2	Monoclonal AntibodiesIBA 01/2019 - 12/2015
2	Chondroitin Sulfate ProteoglycansIBA 01/2018 - 08/2008
2	Fingolimod Hydrochloride (FTY720)FDA Link 01/2018 - 03/2014
2	anti-aquaporin 4 autoantibodyIBA 12/2017 - 01/2014
2	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2017 - 12/2014
2	Protein Isoforms (Isoforms)IBA 01/2017 - 09/2006
2	Biological ProductsIBA 01/2017 - 02/2004
2	Cholinergic ReceptorsIBA 11/2016 - 01/2014
2	ChemokinesIBA 11/2016 - 08/2014
2	Carbon MonoxideIBA 01/2016 - 05/2015
2	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)IBA 01/2016 - 01/2012
2	Carnitine (L-Carnitine)FDA LinkGeneric 06/2015 - 01/2011

Therapy/Procedure

20	Therapeutics 06/2022 - 02/2005
4	Tracheostomy 01/2020 - 01/2008
2	Thymectomy 12/2019 - 09/2019
2	Spinal Injections 01/2019 - 01/2006
2	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 06/2015 - 01/2013